Janssen announces survival data from phase III MAIA study of daratumumab in patients with newly diagnosed multiple myeloma who are transplant ineligible

Study showed after median follow-up of ~5 years, addition of daratumumab to lenalidomide and dexamethasone (LD) resulted in statistically significant survival benefit over LD alone (32% reduction in risk of death; median not reached in either arm;HR 0.68,95 CI,0.53-0.86;p=0.0013)

Source:

Biospace Inc.